COPD Therapeutics in Major Developed Markets Forecast to year 2021: 1 | 页面 4

3.1 Product Profiles 22
3.1.1 Bronchodilator and Inhaled Corticosteroid Combination Therapy 22
3.1.2 Bronchodilator Monotherapy 24
3.1.3 Bronchodilator Combination Therapy 28
3.1.4 Alternative Therapy 30
3.1.5 Conclusion 31
3.1.6 Unmet Needs 32
4 COPD Pipeline 33
4.1 Molecular Target Analysis 35
4.2 Clinical Trials 40
4.2.1 Failure Rate 40
4.2.2 Clinical Trial Duration 42
4.2.3 Clinical Trial Size 44
4.2.4 Comparative Clinical Trial Metrics Analysis 48
4.3 Promising Pipeline Molecules 49
4.3.1 Mepolizumab - GSK 49
4.3.2 Vilanterol Trifenatate - GSK/Theravance 50
4.3.3 Fluticasone Furoate + Umeclidinium Bromide + Vilanterol Trifenatate - GSK 51
4.3.4 Budesonide + Formoterol Fumarate + Glycopyrronium (PT010) - AstraZeneca/Pearl
Therapeutics 53
4.3.5 Glycopyrronium + Formoterol Fumarate (PT003) - AstraZeneca/Pearl Therapeutics 54
4.3.6 Glycopyrronium + Formoterol Fumarate Forecast 55
4.3.7 Benralizumab - AstraZeneca/MedImmune 56
4.3.8 TD-4208 - Theravance 57
4.3.9 Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium - Chiesi Farmaceutici
59